Peptonic Medical AB (publ) - Publishes financial report for the second quarter 2026

Peptonic Medical AB (publ) ("Peptonic" or the "Company") publishes today, August 19, 2026, financial report for the second quarter 2026. 

Key figures for the Group – Second quarter (April - June)

• Sales of goods amounted to KSEK 2 360 (4 912).
• Gross profit amounted to KSEK 1 415 (4 783), corresponding to a gross margin of 60 (97) percent.
• Operating profit amounted to KSEK -3 711 (-3489).
• Earnings per share amounted to SEK -0,0002 (-0,0004).

Key figures for the Mother company - Second quarter (April - June)

• Sales of goods amounted to KSEK 2 352 (3558).
• Gross profit amounted to KSEK 1 408 (1139), corresponding to a gross margin of 60 (32) percent.
• Operating loss amounted to KSEK -3530 (-1987)

Significant events during the second quarter

28 APR Provides an update on the product Vernivia and the ongoing MDR process for updating the CE marking.

20 MAJ The company announces the expansion of its portfolio and the launch of VagiVital Intimate V Wipes, intimate wipes.

22 MAJ The company announces the broadening of its portfolio and the launch of VagiVital Moisturizing Intimate Cream, a new product in moisturizing intimate care.

3 JUN Peptonic announces the launch of a new product segment within health and beauty. The first product will be a dietary supplement that is a functional beauty blend powder developed to support skin structure, hair and nails, and contribute to energy and general well-being.

10 JUN The first delivery under the Company's US partnership agreement has been shipped. The delivery represents an important milestone in Peptonic's international expansion and marks the transition from the preparatory phase to commercial delivery within the partnership.

15 JUN The company announced the outcome of the warrants of series TO6. A total of 6,855,452,671 TO6, corresponding to approximately 60.2 percent of the outstanding TO6, were exercised for the subscription of 6,855,452,671 shares at a subscription price of SEK 0.0011 per share. Through the exercise of the Warrants, Peptonic received approximately SEK 7.5 million before deductions for issue costs and set-offs.

24 JUN The Annual General Meeting was held, the meeting decided, among other things, on the adoption of the income statement and balance sheet, the appropriation of profits, the discharge of liability for the members of the Board of Directors and the CEO. The meeting also decided on the election of Carina Lindqvist as a board member.

After the end of the period

11 AUG Board member Tarek Shoeb announced that due to new external assignments, he can no longer represent Peptonic's board and is thus making his seat available.

Comments by the CEO

After the second quarter, we can see that Peptonic continues to take important steps in the phase that the company entered after the completed reconstruction and the extensive change work that has been carried out over the past year. Today, we have a clearer and more focused business, a lower cost base and better conditions to direct our resources towards growth, sales and product development.

One of the most important events of the quarter was the completion of production and delivery of our first order to our strategic partner in the USA. During the summer, the product was launched under the partner's own brand in North America and the UK. The feedback we have received so far is very positive and, according to our partner, the launch has been successful. Thousands of women have now had access to products based on our technology. This is an important milestone and concrete proof of the international potential that exists in our product portfolio.

In parallel, we continue to broaden our offering. During the quarter, we communicated three upcoming product launches that are important parts of the ambition to develop VagiVital into a broader and stronger brand in women's health.

The process of updating the CE marking for Vernivia continues during the autumn. An updated CE marking is an important prerequisite for a relaunch of our antibiotic-free mousse for self-care treatment of bacterial vaginosis.

Financially, we have taken another step forward. In June, the planned capital raising was completed through the use of warrants. Just over 60 percent of all warrants were exercised, which strengthened liquidity and reduced the company's debt by approximately SEK 7.5 million. Together with the lower cost base, this gives us better conditions to focus on continued commercial development.

In the first quarter, I described how we had created the conditions for Peptonic's next phase. During the second quarter, we have begun to translate these conditions into concrete commercial development. Our international launch, the ongoing broadening of the product portfolio and a strengthened financial position give us a good foundation for continued work.

Our focus going forward is clear: stronger products, increased sales and continued brand building. We will continue to develop our products, build on our partnerships and create the conditions for long-term and sustainable growth.

Daniel Rudeklint,

Interim CEO

The interim report is available on the company's website: https://www.peptonicmedical.se/finansiell-information/

For further information, please contact:
Daniel Rudeklint, interim CEO Peptonic Medical AB

Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73

About Peptonic Medical AB                           

Peptonic Medical AB (publ) is a Swedish medical technology company that develops and sells clinically proven self-care products in intimate women's health. Under the brands VagiVital and Vernivia, the Company offers an over-the-counter portfolio of effective and gentle products that help women understand, treat and prevent common medical conditions in the genital area. Peptonic's growth strategy is based on geographic expansion, especially in the US and Europe, and on continuously strengthening the product portfolio through its own product development and strategic acquisitions.

The company is headquartered in Stockholm, Sweden, and has subsidiaries Peptonic Medical Inc. and Common Sense Marketing Inc. in the United States. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.